The proposed study is a phase 1, open label, randomized study to evaluate the safety and
antiretroviral activity of seven infusions of 3BNC117 and 10-1074, administered intravenously
at 30 mg/kg dose level, in human immunodeficiency virus (HIV)-infected individuals on
combination antiretroviral therapy (ART) and during an analytical interruption of ART.
Phase:
Phase 1
Details
Lead Sponsor:
Rockefeller University
Collaborators:
Montefiore Medical Center National Institute of Allergy and Infectious Diseases (NIAID) Ragon Institute of MGH, MIT and Harvard